Product Pipeline

Unmet Medical Need in CRS

Of the 27 million people with CRS, 3.5 million are under the care of an ENT specialist. Many others are treated through their primary care physician, which collectively results in 18-22 million annual doctor visits1 and health care expenditures that total more than $9 billion per year in the U.S.2

There is no approved pharmaceutical treatment for CRS. Current treatment options consist of intranasal corticosteroid sprays approved for nasal polyposis, oral steroids and endoscopic sinus surgery. Of the patients on medical therapy, 40-60% fail treatment, and sinus surgery has not been demonstrated to confer additional benefit to that obtained by medical treatment.3 While oral steroids can be effective, their side effects profile inhibit routine use.

1Benninger MS et al., Otolaryngol Head Neck Surg 2003;129S:S1-S32
2Smith, K.A., et al., Laryngoscope, 2015. 125(7): p. 1547-56
3Khalil H, Nunez D. Functional endoscopic sinus surgery for chronic rhinosinusitis. The Cochrane Library. July 2006.